ISSN:
1432-1041
Keywords:
Hypertension
;
Ketanserin
;
platelet aggregation
;
serotonin
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary The 5-HT2-receptor antagonist ketanserin (20–40 mg b.i.d.) was administered to 62 patients of both sexes with uncomplicated primary hypertension. After 4 weeks of treatment about 50% of the patients had reached the target diastolic blood pressure of 90 mm Hg or below. Interindividual variability was large. In a retrospective analysis the variability could not be explained by sex or the dose of ketanserin. There was a weak association between age and systolic blood pressure response (r=0,24; P=0.06), which could be entirely accounted for by the higher base line blood pressure in the elderly patients. In one group of patients (n=12), the ex vivo aggregation to serotonin (10−6 M) was studied during treatment with placebo and ketanserin. Ketanserin completely inhibited 5-HT-induced aggregation in all patients. There was a close correlation between the area under the 5-HT-induced platelet aggregation curve during placebo and the subsequent reduction in diastolic blood pressure after 4 weeks of treatment with ketanserin. The present data suggest that the blood pressure response to ketanserin can be predicted from the ex vivo sensitivity of platelets to serotonin. By implication, they also support a role for serotonergic mechanisms in hypertension.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00315468
